Literature DB >> 17546687

Versatile RHDV virus-like particles: incorporation of antigens by genetic modification and chemical conjugation.

Matthew Peacey1, Sarah Wilson, Margaret A Baird, Vernon K Ward.   

Abstract

Virus-like particles have proved to be excellent molecular scaffolds, yet the individual characteristics and immune responses generated against each VLP requires the development of a wide range of capsids for use as vaccines, molecular delivery vessels, and nanoscale templates. Here we describe the development of Rabbit haemorrhagic disease virus (RHDV)-like particles as a rapidly versatile molecular workbench, overcoming limitations imposed by established genetic antigen incorporation procedures with chimeric VLP. Production of the RHDV capsid protein in a baculovirus system led to the self-assembly of VLP which were recovered at over 99% purity and manipulated both genetically and chemically. Fusion of small peptide sequences to RHDV VLP was well tolerated, forming chimeric capsids that enhanced the presentation of foreign peptide to hybridoma T helper cells 700-fold. Rapid and simple conjugation techniques employing the hetero-bifunctional chemical linker sulfo-SMCC enabled both small peptides and whole proteins to be conjugated to the surface of RHDV VLP, overcoming limitations imposed on VLP formation and yield experienced with chimeric VLP. Administration of VLP/ovalbumin conjugate provoked high titre ovalbumin-specific antibody in mice, demonstrating the immune stimulatory properties of the capsid were conferred to conjugated foreign antigen. VLP facilitated delivery of conjugated antigen to dendritic cells, eliciting proliferative responses in naïve TCR transgenic T helper cells that were at least 10-fold greater than ovalbumin antigen delivered alone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17546687     DOI: 10.1002/bit.21518

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  32 in total

Review 1.  Virus-based nanoparticles as platform technologies for modern vaccines.

Authors:  Karin L Lee; Richard M Twyman; Steven Fiering; Nicole F Steinmetz
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-19

2.  Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity.

Authors:  Jaina M Patel; Vincent F Vartabedian; Min-Chul Kim; Sara He; Sang-Moo Kang; Periasamy Selvaraj
Journal:  Biotechnol Bioeng       Date:  2015-04-17       Impact factor: 4.530

Review 3.  Ferritin-based drug delivery systems: Hybrid nanocarriers for vascular immunotargeting.

Authors:  Makan Khoshnejad; Hamideh Parhiz; Vladimir V Shuvaev; Ivan J Dmochowski; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2018-03-06       Impact factor: 9.776

4.  Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles.

Authors:  Sharmila Pejawar-Gaddy; Yogendra Rajawat; Zoe Hilioti; Jia Xue; Daniel F Gaddy; Olivera J Finn; Raphael P Viscidi; Ioannis Bossis
Journal:  Cancer Immunol Immunother       Date:  2010-07-21       Impact factor: 6.968

5.  High-resolution cryo-electron microscopy structures of murine norovirus 1 and rabbit hemorrhagic disease virus reveal marked flexibility in the receptor binding domains.

Authors:  Umesh Katpally; Neil R Voss; Tommaso Cavazza; Stefan Taube; John R Rubin; Vivienne L Young; Jeanne Stuckey; Vernon K Ward; Herbert W Virgin; Christiane E Wobus; Thomas J Smith
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

6.  Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis.

Authors:  Florian Krammer; Theresa Schinko; Paul Messner; Dieter Palmberger; Boris Ferko; Reingard Grabherr
Journal:  J Virol Methods       Date:  2010-03-19       Impact factor: 2.014

Review 7.  Biomedical and Catalytic Opportunities of Virus-Like Particles in Nanotechnology.

Authors:  B Schwarz; M Uchida; T Douglas
Journal:  Adv Virus Res       Date:  2016-11-08       Impact factor: 9.937

8.  Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation.

Authors:  Nicholas M Molino; Amanda K L Anderson; Edward L Nelson; Szu-Wen Wang
Journal:  ACS Nano       Date:  2013-10-09       Impact factor: 15.881

9.  An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy.

Authors:  Khairunadwa Jemon; Vivienne Young; Michelle Wilson; Sara McKee; Vernon Ward; Margaret Baird; Sarah Young; Merilyn Hibma
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

10.  Delivering Two Tumour Antigens Survivin and Mucin-1 on Virus-Like Particles Enhances Anti-Tumour Immune Responses.

Authors:  Katrin Campbell; Vivienne L Young; Braeden C Donaldson; Matthew J Woodall; Nicholas J Shields; Greg F Walker; Vernon K Ward; Sarah L Young
Journal:  Vaccines (Basel)       Date:  2021-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.